Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeated Subcutaneous (SC) Doses of REMD-477 in Subjects With Type 2 Diabetes Mellitus

NCT02455011 is registered in ClinicalTrials.gov with REMD Biotherapeutics, Inc. as lead sponsor.

NCT NCT02455011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02455011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeated Subcutaneous (SC) Doses of REMD-477 in Subjects With Type 2 Diabetes Mellitus
Lead sponsor
REMD Biotherapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2015
Completion date
February 28, 2018
Enrollment
75 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, type 2 diabetes mellitus